Drug intelligence / Profile preview

RE-04

Development stage: Preclinical
Lead developer: Reconnect Labs
Modality: Small Molecules
Administration: Subcutaneous

Overview

RE-04 is a preclinical-stage small molecule inhibitor of dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK-1A) being developed by Reconnect Labs. The drug is designed to promote pancreatic beta cell regeneration, offering a potential disease-modifying therapeutic approach for the treatment of diabetes. By inhibiting DYRK-1A, RE-04 aims to stimulate the proliferation and functional recovery of insulin-producing beta cells, addressing the underlying pathology of insulin deficiency. Reconnect Labs is currently advancing RE-04 through IND-enabling studies.

Targets

MAOA (Monoamine oxidase A)DYRK3 (Dual-specificity tyrosine-phosphorylation-regulated kinase 3)CLK (CDC-like kinase family)DYRK1A (Dual-specificity tyrosine-phosphorylation-regulated kinase 1A)

Beyond the preview

Go deeper on RE-04.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RE-04.

Explore the full profile